Fri, Jul 11, 2014, 3:32 PM EDT - U.S. Markets close in 28 mins.

Recent

% | $
Quotes you view appear here for quick access.

GOL Linhas A Message Board

toss30041 11 posts  |  Last Activity: Jun 3, 2014 12:31 PM Member since: Sep 23, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    FEYE Conference Call in 15 minutes

    by toss30041 Jun 3, 2014 10:17 AM
    toss30041 toss30041 Jun 3, 2014 12:31 PM Flag

    Merrill Lynch BOFA Technology Conference. May be a link for playback on the Fireeye website. It was pretty impressive.... especially the part about the competition not being able to hold a candle to the detection rate of FEYE products. I came away with the impression they are "shooting ducks in a barrel". The market potential is enormous

  • Reply to

    FEYE Conference Call in 15 minutes

    by toss30041 Jun 3, 2014 10:17 AM
    toss30041 toss30041 Jun 3, 2014 11:22 AM Flag

    on the web.... almost over. Says Visibility is getting Better/Increasing. The renewal rates are Extremely High. And Cross Sales are Very Strong. Commenting about the drop in stock price... says most of the Employees have joined the company in the past year, and cannot sell the stock. Says if you look back one year from now, you will see this was an Opportunity

  • Reply to

    FEYE Conference Call in 15 minutes

    by toss30041 Jun 3, 2014 10:17 AM
    toss30041 toss30041 Jun 3, 2014 11:11 AM Flag

    Says their strategy has been "Win the Government, Win the Market".... which they are doing. And also the Telco's. Says FireEye products are "disrupting" the existing models being used in the market. The existing anti-virus & other protection strategies are not working. And FireEye has the ONLY products that detect the advanced threats

  • Reply to

    FEYE Conference Call in 15 minutes

    by toss30041 Jun 3, 2014 10:17 AM
    toss30041 toss30041 Jun 3, 2014 11:01 AM Flag

    DeWalt says we are just now leaving the 1st Inning.... which was all about "education". Which has been helped along by the media. As we move into the 2nd inning, companies are wondering whether they should be renewing their Anit-Virus programs and Firewalls. And FireEye is being Swamped with calls from Companies from all Countries around the world. This is really early, and its going to be HUGE!

  • Reply to

    FEYE Conference Call in 15 minutes

    by toss30041 Jun 3, 2014 10:17 AM
    toss30041 toss30041 Jun 3, 2014 10:55 AM Flag

    David DeWalt just said the competing products from CSCO, IBM and Palo Alto detection rate are near ZERO%. Because of where they sit on the network. FireEye's detection rate is significant, so the competition is pretty much non-existent. Looks like Rick Sherland was right.... FEYE's products are 2nd to none

  • FEYE Conference Call starts at 10:30ET. More positive news coming out in a few minutes

  • WOW! Somebody betting LARGE today on a Gap Higher. Or Short Sellers are starting to get scared..... and trying to hedge against an explosion higher.

  • Analyst at Griffin says it's worth $13. Google this:

    Don't Miss the Boat on Big Biotech Catalysts Keith Markey

  • Reply to

    Valuewalk article on MNKD - from 1 hour ago

    by toss30041 Apr 15, 2014 12:16 PM
    toss30041 toss30041 Apr 15, 2014 12:25 PM Flag

    with their estimate of 3.6 Billion in Sales for 2015.... here is breakdown on potential targets based on Price/Sales:

    1x Sales = $10/share
    2x Sales = $20/share
    3x Sales = $30/share
    4x Sales = $40/share

    I wonder how long this stock can stay in single digits?

  • Reply to

    Valuewalk article on MNKD - from 1 hour ago

    by toss30041 Apr 15, 2014 12:16 PM
    toss30041 toss30041 Apr 15, 2014 12:19 PM Flag

    Typo error..... 2015 Sales are estimated at 3.6 Billion.... not 2025.

  • MannKind presents a good buying opportunity

    Presently, MannKind Corporation (NASDAQ:MNKD)’s Afrezza, which is an inhaled diabetes device, is under review by the FDA. Earlier this month, shares of the drug maker surged following the approval from the FDA advisory panel over the use of Afrezza for Type 2 diabetes. The panel also recommended the device for Type 1 diabetes. However, after the news that the FDA has postponed the decision until mid-July, the shares have been moving downwards.

    A report from Brinson Patrick on April 8, 2014 by analyst Christopher S James views the recent dip in MannKind Corporation (NASDAQ:MNKD)’s shares as a good buying opportunity believing “a high level of conviction for approval.” Afrezza has already won the approval from AdCom for type-1 and type-2 diabetes, which raises the chances of FDA approval.

    According to James, Afrezza could start selling from the first quarter of 2015, and he expects 2025 sales to be around $3.6 billion, “driven by use in earlier-stage T2D.” The analyst expects the initial demand for Afrezza to be high “considering statements made by the panel and open public hearing about its efficacy, safety, pharmacokinetics, and attractive size.”

    Brinson Patrick has a Market Outperform rating on MannKind Corporation (NASDAQ:MNKD) with a price target of $12. At 11 a.m. EDT, MannKind Corporation (NASDAQ:MNKD) shares were down 3.18% to $6.09.

GOL
6.11+0.24(+4.09%)3:30 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.